Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APLNR | P35414 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1986520 | 0.84 | — | — | |
| SCHEMBL22906 | 0.78 | APLNR (0.31) | APLNR | |
| SCHEMBL580930 | 0.74 | APLNR (0.32) | APLNR | |
| SCHEMBL21065 | 0.74 | NAAA (0.34) | — | |
| SCHEMBL16068451 | 0.74 | NAAA (0.38) | — | |
| SCHEMBL22907 | 0.72 | APLNR (0.55) | APLNR | |
| SCHEMBL16911410 | 0.72 | APLNR (0.31) | APLNR | |
| SCHEMBL102863 | 0.72 | NCF1 (0.39) | APLNR | |
| SCHEMBL16499990 | 0.72 | APLNR (0.31) | APLNR | |
| SCHEMBL178339 | 0.72 | KDM4E (0.42) | APLNR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230115350-A1 | TEAD INHIBITORS AND USES THEREOF | CEDILLA THERAPEUTICS, INC. | 2023-04-13 | — | — | US | disclosed |
| WO-2023009785-A1 | TEAD INHIBITORS AND USES THEREOF | CEDILLA THERAPEUTICS, INC. (US) | 2023-02-02 | — | — | WO | disclosed |
| WO-2023009785-A1 | TEAD INHIBITORS AND USES THEREOF | CEDILLA THERAPEUTICS, INC. (US) | 2023-02-02 | — | — | WO | disclosed |
| US-20180044343-A1 | BICYCLIC IMIDAZOLO DERIVATIVE | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2018-02-15 | — | — | US | disclosed |
| US-20180044343-A1 | BICYCLIC IMIDAZOLO DERIVATIVE | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2018-02-15 | — | — | US | disclosed |
| WO-2016147659-A1 | BICYCLIC IMIDAZOLO DERIVATIVE | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2016-09-22 | — | — | WO | disclosed |
| EP-2114937-B1 | PHENOTHIAZIN DERIVATES, METHOD FOR THE PRODUCTION THEREOF AND USE THEREOF AS PHARMACEUTICALS | SANOFI AVENTIS (FR) | 2011-06-29 | — | — | EP | disclosed |
| US-7732440-B2 | Phenothiazin derivatives, method for the production thereof and use thereof as pharmaceuticals | SANOFI-AVENTIS (FR) | 2010-06-08 | — | — | US | disclosed |
| US-20090325942-A1 | PHENOTHIAZIN DERIVATES, METHOD FOR THE PRODUCTION THEREOF AND USE THEREOF AS PHARMACEUTICALS | SANOFI-AVENTIS (FR) | 2009-12-31 | — | — | US | disclosed |
| EP-2114937-A1 | PHENOTHIAZIN DERIVATES, METHOD FOR THE PRODUCTION THEREOF AND USE THEREOF AS PHARMACEUTICALS | Sanofi-Aventis (FR) | 2009-11-11 | — | — | EP | disclosed |
| WO-2008089892-A1 | PHENOTHIAZIN DERIVATES, METHOD FOR THE PRODUCTION THEREOF AND USE THEREOF AS PHARMACEUTICALS | SANOFI-AVENTIS (FR) | 2008-07-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180044343-A1 | BICYCLIC IMIDAZOLO DERIVATIVE | PDE3A, PDE2A, PDE5A | APLNR 4765/4885 |
| US-20230115350-A1 | TEAD INHIBITORS AND USES THEREOF | TEAD2, TEAD3, TEAD4 | APLNR 4725/4885 |
| US-20090325942-A1 | PHENOTHIAZIN DERIVATES, METHOD FOR THE PRODUCTION THEREOF AND USE THEREOF AS PHARMACEUTICALS | CYP2D6, CYP1B1, CYP4B1 | APLNR 3420/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.